Universe Pharmaceuticals ... (UPC)
Universe Pharmaceuticals INC Statistics
Share Statistics
Universe Pharmaceuticals INC has 216.53K shares outstanding. The number of shares has increased by -0.24% in one year.
Shares Outstanding | 216.53K |
Shares Change (YoY) | -0.24% |
Shares Change (QoQ) | -0.05% |
Owned by Institutions (%) | 0.47% |
Shares Floating | 213.06K |
Failed to Deliver (FTD) Shares | - |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 159.9K, so 7.6% of the outstanding shares have been sold short.
Short Interest | 159.9K |
Short % of Shares Out | 7.6% |
Short % of Float | 8.14% |
Short Ratio (days to cover) | 0.11 |
Valuation Ratios
The PE ratio is -335.26 and the forward PE ratio is null. Universe Pharmaceuticals INC's PEG ratio is 11.38.
PE Ratio | -335.26 |
Forward PE | n/a |
PS Ratio | 63.95 |
Forward PS | null |
PB Ratio | 52.27 |
P/FCF Ratio | 1920.46 |
PEG Ratio | 11.38 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Universe Pharmaceuticals INC.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.14.
Current Ratio | 2.68 |
Quick Ratio | 2.43 |
Debt / Equity | 0.14 |
Debt / EBITDA | -1.71 |
Debt / FCF | 5.1 |
Interest Coverage | -22.49 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $143.59K |
Profits Per Employee | $-27.39K |
Employee Count | 225 |
Asset Turnover | 0.61 |
Inventory Turnover | 6.58 |
Taxes
Income Tax | 2.31M |
Effective Tax Rate | -60.1% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.57, so Universe Pharmaceuticals INC's price volatility has been higher than the market average.
Beta | 1.57 |
52-Week Price Change | null% |
50-Day Moving Average | 7.21 |
200-Day Moving Average | 644.4 |
Relative Strength Index (RSI) | 36.35 |
Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Universe Pharmaceuticals INC had revenue of 32.31M and earned -6.16M in profits. Earnings per share was -1.7.
Revenue | 32.31M |
Gross Profit | 10.32M |
Operating Income | -3.53M |
Net Income | -6.16M |
EBITDA | -3.22M |
EBIT | -3.69M |
Earnings Per Share (EPS) | -1.7 |
Balance Sheet
The company has 5.29M in cash and 5.48M in debt, giving a net cash position of -197.21K.
Cash & Cash Equivalents | 5.29M |
Total Debt | 5.48M |
Net Cash | -197.21K |
Retained Earnings | 10.16M |
Total Assets | 49.43M |
Working Capital | 12.92M |
Cash Flow
In the last 12 months, operating cash flow was 1.12M and capital expenditures -44.17K, giving a free cash flow of 1.08M.
Operating Cash Flow | 1.12M |
Capital Expenditures | -44.17K |
Free Cash Flow | 1.08M |
FCF Per Share | 0.3 |
Margins
Gross margin is 31.93%, with operating and profit margins of -10.92% and -19.08%.
Gross Margin | 31.93% |
Operating Margin | -10.92% |
Pretax Margin | -11.91% |
Profit Margin | -19.08% |
EBITDA Margin | -9.95% |
EBIT Margin | -10.92% |
FCF Margin | 3.33% |
Dividends & Yields
UPC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for UPC.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 24, 2025. It was a backward split with a ratio of 1:40.
Last Split Date | Mar 24, 2025 |
Split Type | backward |
Split Ratio | 1:40 |
Scores
Altman Z-Score | -0.34 |
Piotroski F-Score | 1 |